Skip to main content
SpringerLink
Log in

Allogeneic Unrelated Donor Blood and Marrow Transplantation

  • Chapter
Hematopoietic Stem Cell Transplantation

Part of the book series: Contemporary Hematology ((CH))

  • 1320 Accesses

Abstract

Allogeneic stem cell transplantation can provide curative therapy for patients with hematologic malignancies, marrow failure states, severe immunodeficiencies, hemoglobinopathies and inherited metabolic diseases [1–8]. Unfortunately, only approximately 25 to 30 percent of patients will have a suitable HLA genotypically identical sibling donor available to facilitate transplant therapy. An extensive family search may find a closely matched related donor for only 3 to 5 percent of patients and, thus, in the 1970s HLA-matched unrelated donors (URD) were considered as an alternative [1–3]. In the early 1980s, registries of volunteer marrow donors were established in Europe and North America, but the extreme polymorphism of the HLA system and the immu-nodominant gene products of the major histocompatibility complex, as well as differential frequencies of HLA phenotypes in different populations, indicated a need for volunteer donor registries of substantial size and great genetic diversity. Over 50 national registries exist in all continents including the National Marrow Donor Program in the United States and the Anthony Nolan Research Centre Registry in the United Kingdom which allow expedited searching for donors among well over 12 million registered volunteer donors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993;328:593–602.

    PubMed  CAS  Google Scholar 

  2. Hansen JA, Clift RA, Thomas ED, Buckner CD, Storb R, Giblett ER. Transplantation of marrow from an unrelated donor to a patient with acute leukemia. N Engl J Med 1980;303:565–567.

    PubMed  CAS  Google Scholar 

  3. Ash RC, Casper JT, Chitambar CR, et al. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med 1990;322:485–494.

    PubMed  CAS  Google Scholar 

  4. Barker JN, Davies SM, DeFor TE, et al. Determinants of survival after human leucocyte antigen-matched unrelated donor bone marrow transplantation in adults. Br J Haematol 2002;118:101–107.

    PubMed  CAS  Google Scholar 

  5. O'Reilly RJ, Dupont B, Pahwa S, et al. Reconstitution in severe combined immunodeficiency by transplantation of marrow from an unrelated donor. N Engl J Med 1977;297:1311–1318.

    Google Scholar 

  6. McGlave PB, Shu XO, Wen W, et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years experience of the National Marrow Donor Program. Blood 2000;95:2219–2225.

    PubMed  CAS  Google Scholar 

  7. Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA matching and marrow cell dose. Blood 1997;89:4226–4235.

    PubMed  CAS  Google Scholar 

  8. Weisdorf DJ, Billett AL, Hannan P, et al. Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood. 1997;90:2962–2968.

    PubMed  CAS  Google Scholar 

  9. NMDP data. www.marrow.org.

    Google Scholar 

  10. Beatty PG, Anasetti C, Hansen JA, et al. Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. Blood 1993;81:249–253.

    PubMed  CAS  Google Scholar 

  11. Davies SM, Shu XO, Blazar BR, et al. Unrelated donor bone marrow transplantation: Influence of HLA A and B incompatibility on outcome. Blood. 1995;86:1636–1642.

    PubMed  CAS  Google Scholar 

  12. Ferrara GB, Bacigalupo A, Lamparelli T, et al. Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain. Blood 2001;98: 3150–3155.

    PubMed  CAS  Google Scholar 

  13. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002;99:4200–4206.

    PubMed  CAS  Google Scholar 

  14. Petersdorf EW, Gooley T, Malkki M, et al. The biological significance of HLA-DP gene variation in haematopoietic cell transplantation. Br J Haematol 2001;112:988–994.

    PubMed  CAS  Google Scholar 

  15. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998;92:3515–3520.

    PubMed  CAS  Google Scholar 

  16. Petersdorf EW, Kollman C, Hurley CK, et al. Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the U.S. National Marrow Donor Program experience. Blood 2001;98:2922–2929.

    PubMed  CAS  Google Scholar 

  17. Petersdorf EW, Longton GM, Anasetti C, et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 1997;89:1818–1823.

    PubMed  CAS  Google Scholar 

  18. Petersdorf EW, Longton GM, Anasetti C, et al. Definition of HLA-DQ as a transplantation antigen. Proc Natl Acad Sci USA 1996;93:15358–15363.

    PubMed  CAS  Google Scholar 

  19. Petersdorf EW, Longton GM, Anasetti C, et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995;86:1606–1613.

    PubMed  CAS  Google Scholar 

  20. Petersdorf EW. Major histocompatibility complex class I alleles and antigens in hematopoietic cell transplantation. N Engl J med 2001;345:1794–1800.

    PubMed  CAS  Google Scholar 

  21. Prasad VK, Heller G, Kernan NA, O'Reilly RJ, Yang SY. The probability of HLA-C matching between patient and unrelated donor at the molecular level: estimations based on the linkage disequilibrium between DNA typed HLA-B and HLA-C alleles. Transplantation 1999;68:1044–1050.

    PubMed  CAS  Google Scholar 

  22. Santamaria P, Reinsmoen NL, Lindstrom AL, et al. Frequent HLA class I and DP sequence mismatches in serologically (HLA-A, HLA-B, HLA-DR) and molecularly (HLA-DRB1, HLA-DQA1, HLA-DQB1) HLA-identical unrelated bone marrow transplant pairs. Blood 1994;83:280–287.

    PubMed  CAS  Google Scholar 

  23. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. From the Japan Marrow Donor Program. N Engl J Med 1998;339:1177–1185.

    PubMed  CAS  Google Scholar 

  24. Schreuder GM, Hurley CK, Marsh SG, et al. The HLA dictionary 2001: a summary of HLA-A, -B, -C, -DRB1/3/4/5, -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -CR, and DQ antigens. Hum Immunol 2001:62:826–849.

    PubMed  CAS  Google Scholar 

  25. Scott I, O'Shea J, Bunce M, et al. Molecular typing shows a high level of HLA class I incompatibility in serologically well matched donor/patient pairs: implications for unrelated bone marrow donor selection. Blood 1998;92: 4864–4871.

    PubMed  CAS  Google Scholar 

  26. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004;104:1923–30.

    PubMed  CAS  Google Scholar 

  27. Davies SM, Kollman C, Anasetti C, et al. Engraftment and survival after unrelated donor bone marrow transplantation: A report from the National Marrow Donor Program (NMDP). Blood 2000;96:4096–4102.

    PubMed  CAS  Google Scholar 

  28. Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 2002;99:1971–1977.

    PubMed  CAS  Google Scholar 

  29. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, Fernandez-Vina M, Flomenberg N, Horowitz M, Hurley CK, Noreen H, Oudshoorn M, Petersdorf E, Setterholm M, Spellman S, Weisdorf D, Williams TM, Anasetti C. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007 Dec 15;110(13):4576–83.

    PubMed  CAS  Google Scholar 

  30. Saarinen-Pihkala UM, Gustafsson G, Ringden O, et al. No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. J Clin Oncol 2001;19:3406–3414.

    PubMed  CAS  Google Scholar 

  31. Davies SM, DeFor TE, McGlave PB, et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow form unrelated or unrelated donors. Am J Med 2001;110:339–346.

    PubMed  CAS  Google Scholar 

  32. Al-Kasim FA, Thornley I, Rolland M, et al. Single-centre experience with alloge-neic bone marrow transplantation for acute lymphoblastic leukemia in childhood: similar survival after matched-related and matched-unrelated donor transplants. Br J Haematol 2002;116:483–490.

    PubMed  CAS  Google Scholar 

  33. Yakoub-Agha I, Mesnil F, Kuentz M, et al. for the French Society of Bone Marrow Transplantation and Cell Therapy. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006;24:5695–702.

    PubMed  Google Scholar 

  34. Eapen M, Rubinstein P, Zhang MJ, et al. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol. 2006;24:145–51.

    PubMed  Google Scholar 

  35. Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ, Antin JH. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007 Apr 1;109(7):3108–14.

    PubMed  CAS  Google Scholar 

  36. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A, Niederwieser D. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant. 2007;39:71–87.

    PubMed  CAS  Google Scholar 

  37. Eapen M, Logan BR, Confer DL, Haagenson M, Wagner JE, Weisdorf DJ, Wingard JR, Rowley SD, Stroncek D, Gee AP, Horowitz MM, Anasetti C. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant. 2007 Dec;13(12):1461–8.

    PubMed  Google Scholar 

  38. Majhail NS, Brunstein CG, Wagner JE. Double umbilical cord blood transplantation. Curr Opin Immunol. 2006;18:571–5.

    PubMed  CAS  Google Scholar 

  39. Sierra J, Storer B, Hansen JA, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. Bone Marrow Transplant 2000;26:397–404.

    PubMed  CAS  Google Scholar 

  40. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998;338:962–968.

    PubMed  CAS  Google Scholar 

  41. Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001;98:2043–2051.

    PubMed  CAS  Google Scholar 

  42. Storek J, Dawson MA, Storer B, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001;97:3380–3389.

    PubMed  CAS  Google Scholar 

  43. Moretta A, Maccario R, Fagioli F, et al. Analysis of immune reconstitution in children undergoing cord blood transplantation. Exp Hematol 2001;29:371–379.

    PubMed  CAS  Google Scholar 

  44. Small TN, Papadopoulos EB, Boulad F, et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood 1999;93:467–480.

    PubMed  CAS  Google Scholar 

  45. Baron F, Storer B, Maris MB, et al. Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning. Biol Blood Marrow Transplant. 2006;12:1176–87.

    PubMed  Google Scholar 

  46. Ochs L, Shu XO, Miller J, et al. Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood 1995;86:3979–3986.

    PubMed  CAS  Google Scholar 

  47. Barker JN, Hough RE, van Burik JA, et al. Serious infections after unrelated donor transplantation in 136 children: impact of stem cell source. Biol Blood Marrow Transplant. 2005;11:362–70.

    PubMed  Google Scholar 

  48. Albano MS, Taylor P, Pass RF, et al. Umbilical cord blood transplantation and cytomegalovirus: post-transplantation infection and donor screening. Blood. 2006;108:4275–82.

    PubMed  CAS  Google Scholar 

  49. Parody R, Martino R, Rovira M, et al; Infectious/Non-infectious Complications Subcommittee of the Grupo Espanol de Trasplante Hematopoyetico (GETH). Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant. 2006;12:734–48.

    PubMed  Google Scholar 

  50. Brunstein CG, Weisdorf DJ, DeFor T, et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a non-myeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood. 2006;108:2874–80.

    PubMed  CAS  Google Scholar 

  51. Hows JM, Passweg JR, Tichelli A, et al; IMUST Study Participating Centers; Late Effects Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Comparison of long-term outcomes after allogeneic hematopoietic stem cell transplantation from matched sibling and unrelated donors. Bone Marrow Transplant. 2006;38:799–805.

    PubMed  CAS  Google Scholar 

  52. Hurley CK, Wagner JE, Setterholm MI, Confer DL. Advances in HLA: practical implications for selecting adult donors and cord blood units. Biol Blood Marrow Transplant. 2006;12(1 Suppl 1):28–33.

    PubMed  Google Scholar 

  53. Confer DL, Miller JP. Optimal donor selection: beyond HLA. Biol Blood Marrow Transplant. 2007;1:83–6.

    Google Scholar 

  54. Bunin N, Carston M, Wall D, et al. Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission. Blood 2002;99:3151–3157.

    PubMed  CAS  Google Scholar 

  55. Busca A, Anasetti C, Anderson G, et al. Unrelated donor or autologous marrow transplantation for treatment of acute leukemia. Blood. 1994;83:3077–3084.

    PubMed  CAS  Google Scholar 

  56. Cornelissen JJ, Carston M, Kollman C, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001;97:1572–1577.

    PubMed  CAS  Google Scholar 

  57. Arnold R, de Witte T, van Biezen A, et al. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant 1998;21:1213–1216.

    PubMed  CAS  Google Scholar 

  58. Smith FO, King R, Nelson G, et al. Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukemia. Br J Haematol 2002;116:716–724.

    PubMed  Google Scholar 

  59. Weisdorf D, Bishop M, Dharan B, et al. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol Blood Marrow Transplant 2002;8:213–220.

    PubMed  Google Scholar 

  60. Woolfrey AE, Anasetti C, Storer B, et al. Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood 2002;99:2002–2008.

    PubMed  CAS  Google Scholar 

  61. Markova M, Barker JN, Miller JS, Arora M, Wagner JE, Burns LJ, MacMillan ML, Douek D, DeFor T, Tan Y, Repka T, Blazar BR, Weisdorf DJ. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial. Bone Marrow Transplant. 2007 Feb;39(4):193–9.

    PubMed  CAS  Google Scholar 

  62. Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myel-ogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2006;24:444–53.

    PubMed  CAS  Google Scholar 

  63. Pavletic SZ, Khouri IF, Haagenson M, et al. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. J Clin Oncol. 2005;23:5788–94.

    PubMed  Google Scholar 

  64. Weisser M, Schleuning M, Ledderose G, et al. Reduced-intensity conditioning using TBI(8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone Marrow Transplant. 2004;34:1083–8.

    PubMed  CAS  Google Scholar 

  65. Porter DL, Collins RH Jr, Hardy C, et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000;95:1214–1221.

    PubMed  CAS  Google Scholar 

  66. Uzunel M, Remberger M, Sairafi D, et al. Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning. Transplantation. 2006;82:913–9.

    PubMed  Google Scholar 

  67. Giralt S, Logan B, Rizzo D, Zhang MJ, Ballen K, Emmanouilides C, Nath R, Parker P, Porter D, Sandmaier B, Waller EK, Barker J, Pavletic S, Weisdorf D. Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. Biol Blood Marrow Transplant. 2007 Jul;13(7):844–52.

    PubMed  Google Scholar 

  68. Brunstein CG, Barker JN, Weisdorf DJ, DeFor TE, Miller JS, Blazar BR, McGlave PB, Wagner JE. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood. 2007 Oct 15;110(8):3064–70.

    PubMed  CAS  Google Scholar 

  69. Komatsu T, Narimatsu H, Yoshimi A, et al. Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan. Ann Hematol. 2007;86:49–54.

    PubMed  CAS  Google Scholar 

  70. Ballen KK, Spitzer TR, Yeap BY, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007;13:82–9.

    PubMed  CAS  Google Scholar 

  71. Lekakis L, Giralt S, Couriel D, et al. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant. 2006;38:421–6.

    PubMed  CAS  Google Scholar 

  72. Brown JR, Kim HT, Li S, et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2006;12:1056–64.

    PubMed  Google Scholar 

  73. Rodriguez R, Nademanee A, Ruel N, et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006;12:1326–34.

    PubMed  Google Scholar 

  74. Deeg HJ, Seidel K, Casper J, et al. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. Biol Blood Marrow Transplant 1999;5:243–252.

    PubMed  CAS  Google Scholar 

  75. Kojima S, Matsuyama T, Kato S, et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood 2002;100:799–803.

    PubMed  CAS  Google Scholar 

  76. Deeg HJ, Amylon ID, Harris RE, et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 2001;7:208–215.

    PubMed  CAS  Google Scholar 

  77. van Burik JA, Weisdorf DJ. Infections in recipients of blood and marrow transplantation. Hematol Oncol Clin North Am 1999;13:1065–1089.

    PubMed  CAS  Google Scholar 

  78. Hoogerbrugge PM, Brouwer OF, Bordigoni P, et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet 1995;345:1398–1402.

    PubMed  CAS  Google Scholar 

  79. Krivit W. Stem cell bone marrow transplantation in patients with metabolic storage diseases. Adv Pediatr 2002;49:359–378.

    PubMed  Google Scholar 

  80. Sullivan KM, Anasetti C, Horowitz M, et al. Unrelated and HLA-nonidentical related donor marrow transplantation for thalassemia and leukemia. A combined report from the Seattle Marrow Transplant Team and the International Bone Marrow Transplant Registry. Ann NY Acad Sci 1998;850:312–324.

    PubMed  CAS  Google Scholar 

  81. Wagner JE, Eapen M, Macmillan ML, et al. Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood. 2006; [Epub ahead of print]

    Google Scholar 

  82. Niederwieser D, Lange T, Cross M, Basara N, Al-Ali H. Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML. Best Pract Res Clin Haematol. 2006;19:825–38. Review.

    PubMed  Google Scholar 

  83. Hamaki T, Kami M, Kanda Y, et al. Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients. Bone Marrow Transplant. 2005;35:549–56.

    PubMed  CAS  Google Scholar 

  84. Lazarus HM, Pérez WS, Klein JP, Kollman C, Bate-Boyle B, Bredeson CN, Gale RP, Geller RB, Keating A, Litzow MR, Marks DI, Miller CB, Douglas Rizzo J, Spitzer TR, Weisdorf DJ, Zhang MJ, Horowitz MM. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br J Haematol. 2006 Mar;132(6):755–69.

    PubMed  Google Scholar 

  85. Michel G, Rocha V, Chevret S, et al. Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis. Blood 2003;102: 4290–4297.

    PubMed  CAS  Google Scholar 

  86. Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the national Marrow Donor Program. Blood 2002;99:1943–1951.

    PubMed  CAS  Google Scholar 

  87. Sierra J, Radich J, Hansen JA, et al. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1997;90:1410–1414.

    PubMed  CAS  Google Scholar 

  88. Bishop MR, Logan BR, Gandham S, Bolwell BJ, Cahn JY, Lazarus HM, Litzow MR, Marks DI, Wiernik PH, McCarthy PL, Russell JA, Miller CB, Sierra J, Milone G, Keating A, Loberiza FR Jr, Giralt S, Horowitz MM, Weisdorf DJ. Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant. 2008 Apr;41(7):635–42.

    PubMed  CAS  Google Scholar 

  89. Lee SJ, Kuntz KM, Horowitz MM, et al. Unrelated door bone marrow transplantation for chronic myeloid leukemia: a decision analysis. Ann Intern Med 1997;127:1080–1088.

    PubMed  CAS  Google Scholar 

  90. Morton AJ, Gooley T, Hansen JA, et al. Association between pretransplant inter-feron-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 1998;92:394–401.

    PubMed  CAS  Google Scholar 

  91. Hehlmann R, Hochhaus A, Kolb JH, et al. Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 1999;94:3668–3677.

    PubMed  CAS  Google Scholar 

  92. Giralt S, Szydlo R, Goldman JM, et al. Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the International Bone Marrow Transplant Registry. Blood 2000;95:410–415.

    PubMed  CAS  Google Scholar 

  93. Lee SJ, Anasetti C, Kuntz KM, et al. The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood 1998;92:4047–4052.

    PubMed  CAS  Google Scholar 

  94. Barker JN, Davies SM, DeFor T, et al. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 2001;97:2957–2961.

    PubMed  CAS  Google Scholar 

  95. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 2001;344:1815–1822.

    PubMed  CAS  Google Scholar 

  96. Ooi J, Iseki T, Takahashi S, et al. A clinical comparison of unrelated cord blood transplantation and unrelated bone marrow transplantation for adult patients with acute leukemia in complete remission. Br J Haematol 2002:118:140–143.

    PubMed  Google Scholar 

  97. Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001;97:2962–2971.

    PubMed  CAS  Google Scholar 

  98. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental blood transplants from unrelated donor. N Engl J Med. 1998;339: 1565–1577.

    PubMed  CAS  Google Scholar 

  99. Locatelli F, Rocha V, Chastang C, et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Blood. 1999;93:3662–3671.

    PubMed  CAS  Google Scholar 

  100. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hema-tologic malignancy. Blood. 2005;105:1343–7.

    PubMed  CAS  Google Scholar 

  101. Remberger M, Ringden O, Blau IW, et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001;98:1739–1745.

    PubMed  CAS  Google Scholar 

  102. Elmaagacli AH, Basoglu S, Peceny R, et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated doors in patients with first chronic phase chronic myeloid leukemia. Blood 2002;99:1130–1135.

    PubMed  CAS  Google Scholar 

  103. Dahlke J, Kroger N, Zabelina T, et al. Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation. Bone Marrow Transplant. 2006;37:155–63.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Minnesota Medical School, Minneapolis, MN

    Daniel Daniel Weisdorf

Authors
  1. Daniel Daniel Weisdorf
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Hematologic Malignancies, Dana-Farber Cancer Institute, 44 Binney Street, DFCI D1B30, Boston, MA, 02115, USA

    Robert J. Soiffer MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Weisdorf, D.D. (2008). Allogeneic Unrelated Donor Blood and Marrow Transplantation. In: Soiffer, R.J. (eds) Hematopoietic Stem Cell Transplantation. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-438-4_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-438-4_13

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-05-3

  • Online ISBN: 978-1-59745-438-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation